FDA Plays

[kei]

NEOP - yes, that's the reason we are here...(not amex listing)

also one more event before those...
http://finance.yahoo.com/news/Neoprobe-to-Present-Lymph-bw-3827106899.html?x=0&.v=1

Press Release Source: Neoprobe Corporation On Wednesday February 9, 2011, 4:05 pm EST

DUBLIN, Ohio--(BUSINESS WIRE)-- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology surgical and diagnostic products, today announced that its President and Chief Executive Officer, David Bupp, will present a business and development update on the Company’s lymphatic-focused technologies on Tuesday, February 15, 2011 at 11:30AM EST in the Basildon Room of the Waldorf Astoria Hotel in New York, NY, during the 13th Annual BIO CEO & Investor Conference.

Mr. Bupp will provide a corporate overview, including an update and discussion of the clinical and regulatory status of Neoprobe’s lead drug development product, Lymphoseek®, and its other proprietary radiopharmaceutical product, RIGScan™ CR. Mr. Bupp's presentation will be accessible live at www.veracast.com/webcasts/bio/ceoinvestor2011/87208478.cfm. An archived version of the webcast will be available for 30 days following the live presentation using the same link.
The presentation at the BIO CEO & Investor Conference will be the Company’s first investor presentation since being approved for listing on the NYSE Amex Exchange. Neoprobe expects to present at a number of investor conferences in the coming months. The Company’s next scheduled presentation following BIO CEO will be at the Cowen and Company 31st Annual Health Care Conference, March 7-9, at The Boston Marriott Copley Place where Dr. Mark Pykett, Neoprobe’s EVP and Chief Development Officer will be providing further business updates.



About Lymphoseek



Lymphoseek is a proprietary radioactive tracing agent being developed for use in connection with gamma detection devices in a surgical procedure known as Intraoperative Lymphatic Mapping (ILM). One Phase 3 multi-center clinical trial for Lymphoseek in patients with breast cancer or melanoma has been successfully completed and a second Phase 3 clinical study in the same patient population is nearing completion to support the filing of a New Drug Application. A third Phase 3 clinical study to evaluate the efficacy of Lymphoseek as a sentinel lymph node tracing agent in patients with head and neck squamous cell carcinoma is underway. Additional information related to ongoing clinical studies being performed with Lymphoseek may be obtained at www.clinicaltrials.gov.



About Neoprobe



Neoprobe is a biomedical company focused on enhancing oncology patient care and improving patient benefit. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScanTM CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com